Rudyk B I, Sabadyshin R A
Kardiologiia. 1991 Nov;31(11):52-4.
Lipid peroxidation (LPO) was studied in 90 patients with chronic heart failure (CHF) in relation to the disease stage. The patients with various CHF showed increased LPO and decreased antioxidative function. Impaired LPO was more pronounced in patients with Stage II CHF. To correct LPO processes, emoxipine, a new synthetic antioxidant, was used in 48 patients. The agent in a dose of 40 mg/day was ascertained to have a regulatory effect on the oxidative-antioxidative system in patients with heart failure. A more profound effect was observed in patients with Stage I patients. The main mechanism of the antioxidative action of emoxipine in CHF was to enhance glutathione reductase and glutathione peroxidase and to lower the level on dienic conjugates in patients with Stage IIB CHF.
对90例慢性心力衰竭（CHF）患者的脂质过氧化（LPO）与疾病阶段的关系进行了研究。不同程度CHF患者的LPO升高，抗氧化功能降低。LPO受损在II期CHF患者中更为明显。为纠正LPO过程，对48例患者使用了一种新型合成抗氧化剂艾莫地平。确定每日40 mg剂量的该药物对心力衰竭患者的氧化-抗氧化系统有调节作用。在I期患者中观察到更显著的效果。艾莫地平在CHF中的抗氧化作用的主要机制是增强谷胱甘肽还原酶和谷胱甘肽过氧化物酶，并降低IIB期CHF患者二烯共轭物水平。
